Sciclone Pharmaceuticals, Inc.

The University of Texas System

Sciclone Pharmaceuticals International, Ltd.

Alfred R Rudolph

Cynthia W Tuthill

Paolo Carminati

Roberto Camerini

Eduardo R Martins

Clarence J Peters

Maria Gabriella Singross, Legal Representative

Maggie Jie Quan

Vincent Chung-Ying Tam

Maria Gabriella Singrossi, Legal Representative

Eric C Mossel

Clarence James Peters

An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.

Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds

An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.

Treatment of melanoma

It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.

Methods of protecting against radiation damage using alpha thymosin

A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.

Thymosin alpha 1 peptide/polymer conjugates

A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.

Treatment of hepatitis C with thymosin and peptide combination therapy

A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin &agr; in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.

Growing community of inventors

Los Altos Hills, CA, United States of America

Alfred R Rudolph